Cargando…
Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects
Thyroid cancer (TC) is the most common endocrine malignancy. TC is classified as differentiated TC (DTC), which includes papillary and follicular subtypes and Hürthle cell variants, medullary TC (MTC), anaplastic TC (ATC), and poorly differentiated TC (PDTC). The standard of care in DTC consists of...
Autores principales: | Puliafito, Ivana, Esposito, Francesca, Prestifilippo, Angela, Marchisotta, Stefania, Sciacca, Dorotea, Vitale, Maria Paola, Giuffrida, Dario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304687/ https://www.ncbi.nlm.nih.gov/pubmed/35872981 http://dx.doi.org/10.3389/fendo.2022.860671 |
Ejemplares similares
-
New Treatment in Advanced Thyroid Cancer
por: Giuffrida, Dario, et al.
Publicado: (2012) -
Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis
por: Puliafito, Ivana, et al.
Publicado: (2023) -
Metabolic complete tumor response in a patient with epidermal growth factor receptor mutant non-small cell lung cancer treated with a reduced dose of afatinib
por: Puliafito, Ivana, et al.
Publicado: (2022) -
Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report
por: Puliafito, Ivana, et al.
Publicado: (2020) -
Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice
por: Gagliano, Ambrogio, et al.
Publicado: (2021)